Dolphin
Senior Member (Voting Rights)
https://www.neurology.org/doi/10.1212/WNL.0000000000205761
GENERAL NEUROLOGY: NEUROIMMUNOLOGY
April 9, 2024
Free Access
Low Vasopressin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (P4-4.006)
Helena Huhmar, Lauri Soinne, Per Sjögren, Bo Christer Bertilson, Per Hamid Ghatan, Björn Bragée, and Olli Polo
AUTHORS INFO & AFFILIATIONS
April 9, 2024 issue
102 (17_supplement_1)
https://doi.org/10.1212/WNL.0000000000205761
Abstract
Objective:
To shed light on the pathophysiology of water homeostasis in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), classified by WHO as a neurological disease (ICD 10 code G933).
Background:
The complex symptomatology of ME/CFS includes signs suggesting abnormal water homeostasis and hypovolemia. Since many patients report polyuria-polydipsia, we conducted an observational series of plasma and urine osmolality as well as plasma levels of vasopressin (VP) in consecutive patients diagnosed with ME/CFS according to the Canadian Consensus Criteria.
Design/Methods:
Plasma and urine osmolality (P-Osm and U-Osm, respectively) and plasma VP levels were measured in 111 patients after overnight fasting and 10-hour fluid deprivation. The clinical routine also included brain MRI and blood chemistry.
Results:
Following the fluid deprivation P-Osm was above normal (>292 mOsm/kg) in 61 patients (55.0%) and U-Osm below normal (< 750 mOsm/kg) in 74 patients (66.7%). VP-levels were below the level of detection (<1.6 pg/mL) in 91 patients (82.0%). A normal level of VP in relation to their P-Osm was found in 11 patients (9.9 %). The state resembling a central type of diabetes insipidus (cDI) would in the absence of hypophyseal imaging findings and blood chemistry consistent with any other hypophyseal hormonal defect be classified as idiopathic.
Conclusions:
Our findings suggest that deficiency of vasopressin secretion is a fundamental measurable part of the disease mechanisms, which may underlie a number of symptoms in ME/CFS, including the common complaint of orthostatic intolerance.
Disclosure: Helena Huhmar has nothing to disclose. Dr. Soinne has nothing to disclose. The institution of Prof. Sjögren has received research support from Patient-led Research Collaboration, US. Prof. Sjögren has received publishing royalties from a publication relating to health care. The institution of Dr. Bertilson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Medect Clinical Trial AB. The institution of Dr. Bertilson has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medect Clinical Trials AB. The institution of Dr. Bertilson has received research support from ME UK. Dr. Bertilson has received intellectual property interests from a discovery or technology relating to health care. Dr. Bertilson has received personal compensation in the range of $500-$4,999 for serving as a teacher with Region Stockholm. Dr. Ghatan has nothing to disclose. Dr. Bragée has nothing to disclose. Dr. Polo has nothing to disclose.
GENERAL NEUROLOGY: NEUROIMMUNOLOGY
April 9, 2024
Free Access
Low Vasopressin in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (P4-4.006)
Helena Huhmar, Lauri Soinne, Per Sjögren, Bo Christer Bertilson, Per Hamid Ghatan, Björn Bragée, and Olli Polo
AUTHORS INFO & AFFILIATIONS
April 9, 2024 issue
102 (17_supplement_1)
https://doi.org/10.1212/WNL.0000000000205761
Abstract
Objective:
To shed light on the pathophysiology of water homeostasis in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), classified by WHO as a neurological disease (ICD 10 code G933).
Background:
The complex symptomatology of ME/CFS includes signs suggesting abnormal water homeostasis and hypovolemia. Since many patients report polyuria-polydipsia, we conducted an observational series of plasma and urine osmolality as well as plasma levels of vasopressin (VP) in consecutive patients diagnosed with ME/CFS according to the Canadian Consensus Criteria.
Design/Methods:
Plasma and urine osmolality (P-Osm and U-Osm, respectively) and plasma VP levels were measured in 111 patients after overnight fasting and 10-hour fluid deprivation. The clinical routine also included brain MRI and blood chemistry.
Results:
Following the fluid deprivation P-Osm was above normal (>292 mOsm/kg) in 61 patients (55.0%) and U-Osm below normal (< 750 mOsm/kg) in 74 patients (66.7%). VP-levels were below the level of detection (<1.6 pg/mL) in 91 patients (82.0%). A normal level of VP in relation to their P-Osm was found in 11 patients (9.9 %). The state resembling a central type of diabetes insipidus (cDI) would in the absence of hypophyseal imaging findings and blood chemistry consistent with any other hypophyseal hormonal defect be classified as idiopathic.
Conclusions:
Our findings suggest that deficiency of vasopressin secretion is a fundamental measurable part of the disease mechanisms, which may underlie a number of symptoms in ME/CFS, including the common complaint of orthostatic intolerance.
Disclosure: Helena Huhmar has nothing to disclose. Dr. Soinne has nothing to disclose. The institution of Prof. Sjögren has received research support from Patient-led Research Collaboration, US. Prof. Sjögren has received publishing royalties from a publication relating to health care. The institution of Dr. Bertilson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Medect Clinical Trial AB. The institution of Dr. Bertilson has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medect Clinical Trials AB. The institution of Dr. Bertilson has received research support from ME UK. Dr. Bertilson has received intellectual property interests from a discovery or technology relating to health care. Dr. Bertilson has received personal compensation in the range of $500-$4,999 for serving as a teacher with Region Stockholm. Dr. Ghatan has nothing to disclose. Dr. Bragée has nothing to disclose. Dr. Polo has nothing to disclose.
Last edited: